Charles River Laboratories International, Inc. Share Price Xetra
Equities
RV6
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
190.7 EUR | -11.64% | 0.00% | 0.00% |
Sales 2024 * | 4.22B 3.88B 331B | Sales 2025 * | 4.53B 4.17B 355B | Capitalization | 10.71B 9.86B 839B |
---|---|---|---|---|---|
Net income 2024 * | 406M 374M 31.81B | Net income 2025 * | 513M 472M 40.19B | EV / Sales 2024 * | 3 x |
Net Debt 2024 * | 1.94B 1.79B 152B | Net Debt 2025 * | 1.46B 1.34B 114B | EV / Sales 2025 * | 2.69 x |
P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
21.3
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.94% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | -11.65% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 31/12/75 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 24/04/22 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 31/03/89 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 31/12/02 |
Virginia Wilson
BRD | Director/Board Member | 68 | 30/09/19 |
Robert Bertolini
BRD | Director/Board Member | 61 | 24/01/11 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+40.29% | 39.03B | |
-11.17% | 26.86B | |
+14.28% | 26.75B | |
-21.40% | 19.03B | |
+0.96% | 12.28B | |
+25.64% | 12.26B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- CRL Stock
- RV6 Stock